Healthcare Market Updates | BioTuesdays by Kilmer Lucas IR

Markets

SVB Leerink starts Amryt Pharma at OP; PT $40

SVB Leerink launched coverage of Amryt Pharma (NASDAQ:AMYT) with an “outperform” rating and $40 price target. The stock closed at $14.15 on Feb. 12. “Filsuvez is poised to be the first approved treatment for...

February 16, 2021

Markets

Ladenburg starts Artelo Biosciences at buy; PT $7

Ladenburg Thalmann initiated coverage of Artelo Biosciences (NASDAQ:ARTL) with a “buy” rating and price target of $7. The stock closed at $1.63 on Feb. 11. Artelo is developing first-in-class, proprietary therapeutics...

February 12, 2021

Markets

HCW starts Plus Therapeutics at buy; PT $7

H.C. Wainwright launched coverage of Plus Therapeutics (NASDAQ:PSTV) with a “buy” rating and $7 price target. The stock closed at $3.75 on Feb. 10. Plus is focused on developing novel therapies against brain cancer. The...

February 11, 2021

Markets

Maxim starts TRACON Pharma at buy; PT $24

Maxim Group initiated coverage of TRACON Pharmaceuticals (NASDAQ:TCON) with a “buy” rating and $24 price target. The stock closed at $9.91 on Feb. 9. TRACON is developing a differentiated anti-PD-L1 checkpoint...

February 10, 2021

Markets

Maxim ups Cyclo Therapeutics PT to $25 from $12

Maxim Group more than doubled its price target for Cyclo Therapeutics (NASDAQ:CYTH) to $25 from $12, citing updates from the Phase 1 and Phase 1/2 clinical programs for Trapsol Cyclo (TC) in Neimann-Pick Type C (NPC)...

February 9, 2021

Markets

SVB Leerink starts Eledon Pharma at OP; PT $34

SVB Leerink launched coverage of Eledon Pharmaceuticals (NASDAQ:ELDN) with an “outperform” rating and a $34 price target. The stock closed at $14.99 on Feb. 5. Eledon is developing AT-1501, a potentially best-in-class...

February 8, 2021

Markets

Maxim ups Lineage PT to $5 from $3

Maxim Group raised its price target for Lineage Cell Therapeutics (NYSE American:LCTX) to $5 from $3, citing an agreement with Neurgain Technologies to develop a novel parenchymal delivery injection (PDI) system for...

February 8, 2021

Markets

Maxim ups BrainStorm Cell Therapeutics to buy from hold; PT $12

Maxim Group upgraded BrainStorm Cell Therapeutics (NASDAQ:BCLI) to “buy” from “hold” with a price target of $12, citing a pullback in the stock since the ALS Phase 3 results in the fourth quarter of 2020, opportunities...

February 4, 2021

Markets

HCW ups Ocugen to buy from neutral; PT $4.50

H.C. Wainwright upgraded Ocugen (NASDAQ:OCGN) to “buy” from “neutral” with a price target of $4.50, citing a definitive agreement with Bharat Biotech to co-develop, supply, and commercialize Bharat’s COVID-19 vaccine...

February 4, 2021

Markets

Dawson Jones starts Aditxt Therapeutics at buy; PT $14

Dawson Jones Securities initiated coverage of Aditxt Therapeutics (NASDAQ:ADTX) with a “buy” rating and $14 price target. The stock closed at $3.34 on Feb. 3. Aditxt has developed a unique antibody test that measures a...

February 4, 2021

Markets

Piper Sandler starts Surgalign at OW; PT $4

Piper Sandler initiated coverage of Surgalign Holdings (NASDAQ:SRGA) with an “overweight” rating and $4 price target. The stock closed at $1.70 on Feb. 1. The pure-play spine provider has made a big investment in a...

February 2, 2021

Markets

BTIG ups Prothena to buy from neutral; PT $29

BTIG upgraded Prothena (NASDAQ:PRTA) to “buy” from “neutral” with a new PT of $29, citing meaningful progress of multiple clinical assets and with the potential for more promising opportunities to emerge near term. The...

February 2, 2021

Markets

SVB Leerink starts Cullinan at OP; PT $52

SVB Leerink initiated coverage of Cullinan Management (NASDAQ:CGEM) with an “outperform” rating and $52 price target. The stock closed at $33.77 on Feb. 1. Cullinan is leveraging a unique “Hub-and-Spoke”...

February 2, 2021

Markets

SVB Leerink starts Lantheus at OP; PT $24

SVB Leerink launched coverage of Lantheus Holdings (NASDAQ:LNTH) with an “outperform” rating and $24 price target. The stock closed at $16.27 on Jan. 29. Lantheus is a leading player in diagnostic nuclear medicine...

February 1, 2021

Markets

WB starts Larimar Therapeutics at OP; fair value estimate $29

William Blair initiated coverage of Larimar Therapeutics (NASDAQ:LRMR) with an “outperform” rating and fair value estimate of $29. The stock closed at $15.44 on Jan. 29. Larimar is developing intracellular-targeted...

February 1, 2021

Markets

AGP starts Viveve Medical at buy; PT $10.75

Alliance Global Partners launched coverage of Viveve Medical (NASDAQ:VIVE) with a “buy” rating and price target of $10.75. The stock closed at $3.55 on Jan. 28. “After two disappointing, yet entirely explainable...

January 29, 2021

Markets

Analysts offer mixed reviews of T2 Biosystems preliminary Q4 results

Analysts for BTIG, Canaccord Genuity and Alliance Global Partners had mixed reviews of preliminary fourth quarter results for T2 Biosystems (NASDAQ:TTOO),a leader in the rapid detection of sepsis-causing pathogens. Mark...

January 27, 2021

Markets

BTIG ups OncoCyte PT to $8 from $5

BTIG raised its price target for OncoCyte (NYSE American:OCX) to $8 from $5, citing a recent direct offering of $25-million with its two largest institutional shareholders, which gives the company “ammunition to execute...

January 26, 2021

Markets

Mackie Research cuts Cipher Pharma to hold; PT to $1 (Canadian) from $1.50

Mackie Research Capital downgraded Cipher Pharmaceuticals (TSX:CPH) to “hold” from “buy” and reduced its price target to $1 (Canadian) from $1.50, citing marketing uncertainty, partially due to a recent unfavorable...

January 25, 2021

Markets

Mackie Research ups Aleafia Health PT to $1.50 (Canadian) from $1

Mackie Research Capital raised its price target for Aleafia Health (TSX:AH) to $1.50 (Canadian) from $1, citing an exclusive agreement with Unifor, Canada’s largest private sector union, to support medical cannabis for...

January 25, 2021

Markets

Ladenburg starts Viridian Therapeutics at buy; PT $40

Ladenburg Thalmann launched coverage of Viridian Therapeutics (NASDAQ:VRDN) with a “buy” rating and $40 price target. The stock closed at $21.78 on Jan. 22. Viridian’s lead asset, VRDN-001, is an anti-IGF-1R monoclonal...

January 25, 2021

Markets

Ladenburg starts Plus Therapeutics at buy; PT $8

Ladenburg Thalmann initiated coverage of Plus Therapeutics (NASDAQ:PSTV) with a “buy” rating and price target of $8. The stock closed at $2.43 on Jan. 22. The company’s lead product, rhenium nanoliposome (RNL), is a...

January 25, 2021

Subscribe